Acceptance rate


Impact factor




JCR rank (Oncology)


JCR rank (Immunology)


2020 total Altmetric mentions


Aims and scope

The Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed, online journal of the Society for Immunotherapy of Cancer (SITC). The journal publishes articles on all aspects of tumor immunology and cancer immunotherapy and, in doing so, aims to enrich communication and advance scientific understanding among the many stakeholders in this rapidly evolving field. Topics of interest range widely across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.

Editorial board

For information about Journal for ImmunoTherapy of Cancer Editor-in-Chief Pedro Romero and his editorial team, please refer to the Editorial Board page.


BMJ publishes JITC on behalf of the Society for Immunotherapy of Cancer.

Journal information

Publication Model Open access
Frequency Continuous
Launch date 2013
Digital Archives Portico, LOCKSS
Indexed by Web of Science Core Collection: Science Citation Index Expanded; MEDLINE, PubMed Central, Science Citation Index Expanded (SCIE), Scopus, DOAJ, Google Scholar
Peer Review Model Single blind; the names of reviewers are hidden from the author
Print ISSN N/A
Online ISSN 2051-1426

Journal Statistics (2020)

Acceptance rate: 33%

Time to first decision: 30 days (mean)
Time from acceptance to publication: 25 days (mean)

Impact Factor (JCR): 13.751
Impact Factor rank : 15/242 (Oncology), 8/162 (Immunology)
5 Year Impact Factor: 13.864
Journal Citation Indicator: 2.29
Eigenfactor: 0.02883
Citescore: 10.4
Citescore rank: 34/340
Scimago Journal rank (SJR): 5.060

2020 total content views: 361,830
2020 total Altmetric mentions: 6,153

The impact that academic research has cannot be defined by one single metric. In 2013, BMJ signed the San Francisco Declaration on Research Assessment (DORA). We did this to show our support for using multiple measures and metrics to portray journals’ impact; moving away from the Impact Factor as a single measure.

How we get these metrics

Contact information

For all contact information please refer to the contact us page.

For authors

Please refer to the Instructions for authors.


Print and online advertising – USA and Canada only

Jim Cunningham
Tel: +1 201.767.4170
Fax: +1 201.767.8065
Information on rates

Online advertising – All countries except USA and Canada

Rights and permissions


The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Its mission is to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field.

BMJ is a founding member of COPE (the Committee on Publication Ethics), which provides a forum for publishers and Editors of scientific journals to discuss issues relating to the integrity of the work submitted to or published in their journals.


The EQUATOR Network is an international initiative that seeks to improve the value of medical research literature by promoting transparent, accurate reporting of research studies. BMJ is a sponsor of its activities.

AllTrials logo

BMJ is a founding organisation of the AllTrials initiative, which calls for all past and present clinical trials to be registered and their results reported.